Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Interest Expenses (2022 - 2026)

Elicio Therapeutics filings provide 2 years of Interest Expenses readings, the most recent being $2000.0 for Q4 2023.

  • On a quarterly basis, Interest Expenses fell 97.83% to $2000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $1.1 million, a 52.66% decrease, with the full-year FY2025 number at $1.1 million, up 149.01% from a year prior.
  • Interest Expenses hit $2000.0 in Q4 2023 for Elicio Therapeutics, up from $1000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.1 million in Q3 2022 to a low of $1000.0 in Q3 2023.